Aligos Therapeutics annual return on equity
2020
2021
2022
2023
2024
2025
Aligos Therapeutics Return on Equity (ROE) Growth & History (ALGS)
Aligos Therapeutics's return on equity was −196.92% for fiscal 2025.
View full Aligos Therapeutics company overviewAligos Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −196.92% | +218.92 pp |
| 2024 | 2024-12-31 | −415.84% | −326.36 pp |
| 2023 | 2023-12-31 | −89.48% | −22.92 pp |
| 2022 | 2022-12-31 | −66.55% | −3.14 pp |
| 2021 | 2021-12-31 | −63.41% | +76.51 pp |
| 2020 | 2020-12-31 | −139.92% | — |
Aligos Therapeutics quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −4.72% | +9.81 pp |
| Q1 2026 | 2026-03-31 | −54.00% | −152.52 pp |
| Q4 2025 | 2025-12-31 | −31.71% | +746.11 pp |
| Q3 2025 | 2025-09-30 | −36.31% | −3.48 pp |
| Q2 2025 | 2025-06-30 | −14.53% | −22.50 pp |
| Q1 2025 | 2025-03-31 | 98.52% | +144.43 pp |
| Q4 2024 | 2024-12-31 | −777.83% | −739.85 pp |
| Q3 2024 | 2024-09-30 | −32.83% | −3.84 pp |
| Q2 2024 | 2024-06-30 | 7.97% | +32.31 pp |
| Q1 2024 | 2024-03-31 | −45.91% | −21.57 pp |
| Q4 2023 | 2023-12-31 | −37.97% | −18.60 pp |
| Q3 2023 | 2023-09-30 | −28.99% | −14.61 pp |
| Q2 2023 | 2023-06-30 | −24.34% | −10.60 pp |
| Q1 2023 | 2023-03-31 | −24.34% | −3.24 pp |
| Q4 2022 | 2022-12-31 | −19.38% | −0.60 pp |
| Q3 2022 | 2022-09-30 | −14.38% | +2.79 pp |
| Q2 2022 | 2022-06-30 | −13.75% | +2.63 pp |
| Q1 2022 | 2022-03-31 | −21.10% | −7.77 pp |
| Q4 2021 | 2021-12-31 | −18.78% | +63.79 pp |
| Q3 2021 | 2021-09-30 | −17.17% | — |
| Q2 2021 | 2021-06-30 | −16.38% | — |
| Q1 2021 | 2021-03-31 | −13.33% | — |
| Q4 2020 | 2020-12-31 | −82.57% | — |
Aligos Therapeutics return on equity trends
Over the last five fiscal years, Aligos Therapeutics's return on equity decreased from −139.92% to −196.92%, a change of −56.99 percentage points. The latest reported quarter, Q2 2026, shows −4.72%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aligos Therapeutics source filings ↗